HDAC9 and neoplasm: For instance, simultaneous inhibition of topoisomerase II and HDAC modulates the immune microenvironment, enhances infiltration of lymphocytes and B cells, and reinstates antitumor immune responses, addressing the constraints of HDAC monotherapy in tumor growth suppression and resistance reversal [16,61].